Hypertrophic cardiomyopathy: Difference between revisions
Acorcoran5 (talk | contribs) No edit summary |
No edit summary |
||
Line 14: | Line 14: | ||
==[[Hypertrophic cardiomyopathy overview|Overview]]== | ==[[Hypertrophic cardiomyopathy overview|Overview]]== | ||
==Hystorical Perspective== | |||
==[[Hypertrophic cardiomyopathy classification|Classification]]== | ==[[Hypertrophic cardiomyopathy classification|Classification]]== | ||
Line 20: | Line 20: | ||
[[Hypertrophic cardiomyopathy genetics|Genetics]] | [[Hypertrophic_cardiomyopathy_histopathology|Histopathologic Abnormalities]] | [[Hypertrophic cardiomyopathy anatomic abnormalities|Anatomic Abnormalities]] | [[Hypertrophic cardiomyopathy outflow obstruction|Outflow Obstruction]] | [[Hypertrophic cardiomyopathy ischemia|Ischemia]] | [[Hypertrophic cardiomyopathy arrhythmogenesis|Arrhythmogenesis]] | [[Hypertrophic cardiomyopathy genetics|Genetics]] | [[Hypertrophic_cardiomyopathy_histopathology|Histopathologic Abnormalities]] | [[Hypertrophic cardiomyopathy anatomic abnormalities|Anatomic Abnormalities]] | [[Hypertrophic cardiomyopathy outflow obstruction|Outflow Obstruction]] | [[Hypertrophic cardiomyopathy ischemia|Ischemia]] | [[Hypertrophic cardiomyopathy arrhythmogenesis|Arrhythmogenesis]] | ||
==[[Hypertrophic cardiomyopathy differential diagnosis|Differentiating Hypertrophic Cardiomyopathy from other Diseases]]== | |||
==[[Hypertrophic cardiomyopathy causes|Causes]]== | ==[[Hypertrophic cardiomyopathy causes|Causes]]== | ||
==[[Hypertrophic cardiomyopathy epidemiology and demographics|Epidemiology and Demographcis]]== | ==[[Hypertrophic cardiomyopathy epidemiology and demographics|Epidemiology and Demographcis]]== | ||
==Risk Factors== | |||
==[[Hypertrophic cardiomyopathy screening|Screening]]== | ==[[Hypertrophic cardiomyopathy screening|Screening]]== | ||
== | ==Natural History, Complications and Prognosis== | ||
==Diagnosis== | ==Diagnosis== |
Revision as of 18:43, 10 December 2019
For patient information click here
Hypertrophic cardiomyopathy | |
![]() | |
---|---|
Hypertrophic cardiomyopathy. Image courtesy of Professor Peter Anderson DVM PhD and published with permission © PEIR, University of Alabama at Birmingham, Department of Pathology |
Hypertrophic Cardiomyopathy Microchapters |
Differentiating Hypertrophic Cardiomyopathy from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Hypertrophic cardiomyopathy On the Web |
Directions to Hospitals Treating Hypertrophic cardiomyopathy |
Risk calculators and risk factors for Hypertrophic cardiomyopathy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and keywords: Hypertrophic cardiomyopathy or HCM, Asymmetric septal hypertrophy or ASH, Hypertrophic obstructive cardiomyopathy, HOCM, Idiopathic hypertrophic subaortic stenosis or IHSS, familial isolated hypertrophic obstructive cardiomyopathy, familial isolated hypertrophic subaortic stenosis, familial or idiopathic hypertrophic subaortic stenosis, familial or idiopathic hypertrophic obstructive cardiomyopathy, primitive hypertrophic obstructive cardiomyopathy, primitive hypertrophic subaortic stenosis, muscular subaortic stenosis, apical hypertrophic cardiomyopathy, which is also known as nonobstructive hypertrophic cardiomyopathy and Japanese variant hypertrophic cardiomyopathy or the Yamaguchi variant (since the first cases described were all in individuals of Japanese descent)
Overview
Hystorical Perspective
Classification
Pathophysiology
Genetics | Histopathologic Abnormalities | Anatomic Abnormalities | Outflow Obstruction | Ischemia | Arrhythmogenesis
Differentiating Hypertrophic Cardiomyopathy from other Diseases
Causes
Epidemiology and Demographcis
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Genetic Testing & Screening | History and Symptoms | Physical examination | Electrocardiogram | Echocardiography | Cardiac MRI | Cardiac CT | Positron Emission Tomography
Treatment
- Medical therapy: Supportive Therapy | Pharmacotherapy
- Invasive therapies: Alcohol Septal Ablation | Septal Myectomy | Ventricular Pacing | Automatic Implantable Cardiac Defibrillator (AICD) Placement | Septal Reduction Therapy Guidelines
Contraindicated medications
Idiopathic hypertrophic subaortic stenosis is considered an absolute contraindication to the use of the following medications:
Special Patient Populations
Asymptomatic Patients | Management During Childhood | Hypotension/Cardiovascular collapse | Pregnancy
2011 ACCF/AHA Guideline Recommendations
Diagnostic testing:
Electrocardiogram | Echocardiography | Stress Testing | Cardiac Magnetic Resonance | Cardiac CT | Positron Emission Tomography
Management:
- Asymptomatic patients: Asymptomatic patients
- Symptomatic patints: Pharmacologic Management
| Invasive Therapies | Alcohol septal ablation | Septal Myectomy | Pacing | Selection of Patients for ICDs | Selection of ICD-Device type | Selection of Patients for Heart Transplantation
- Special Clinical Scenarios: Patients With LV Systolic Dysfunction | Sudden cardiac death Risk Stratification | Participation in Competitive or Recreational Sports and Physical Activity | Management of Atrial Fibrillation | Pregnancy/Delivery | Concomitant Coronary Disease